Akahoshi Takayuki
Department of Cataract and Refractive Surgery, Nihonbashi Cataract-Clinic, Tokyo, Japan.
Clin Ophthalmol. 2024 Sep 4;18:2521-2529. doi: 10.2147/OPTH.S478292. eCollection 2024.
To analyze the patient-reported-outcomes obtained after trifocal intraocular lens (IOL) bilateral implantation in Japanese patients using three different validated questionnaires.
Fifty-three patients implanted with the FineVision HP IOLs (Beaver-Visitec International, Inc. USA) were enrolled in this prospective-study. At 3-months, refraction (spherical equivalent [SE] and cylinder), logMAR uncorrected distance visual acuity (UDVA), and corrected distance visual acuity (CDVA) were obtained. Specifically, patient-reported-outcomes were evaluated using the NEI VFQ-25, the Catquest-9SF, and the PRSIQ questionnaires.
The mean SE and refractive cylinder were 0.00±0.22D and -0.07±0.23D, respectively. A 98.11% of eyes were within ±0.50D and 100% were within ±1.00D of the SE. A 93.40% of the eyes showed equal or less than 0.50D of astigmatism and 100% of eyes equal or less than 1.00D. The mean value for monocular UDVA was -0.05±0.07 logMAR and the mean value for monocular CDVA was -0.07±0.06 logMAR. 87.74% and 92.45% of the eyes showed 20/20 or better monocular UDVA and CDVA, respectively, with 97.17% and 98.11% showing 20/25 or better for UDVA and CDVA, respectively. The NEI VFQ-25 outcomes showed very high scores across all categories, with mean general vision, distance and near activities values of 86.70±6.35, 96.23±7.72 and 92.14±10.74, respectively. The outcomes for the Catquest-9SF questionnaire showed that 90.57% of patients did not report difficulty in their everyday-life with their sight, and 100% of them were "very or quite satisfied" with their sight at present. The PRSIQ outcomes revealed that 100%, 98.11% and 98.11% of patients did not need glasses or contacts for far, intermediate and near vision, respectively.
The results of the patient-reported-outcomes questionnaires indicated that patients implanted bilaterally with the FineVision HP IOL have high vision and health related quality-of-life scores, with a high spectacle independence rate and high patient satisfaction.
使用三种经过验证的问卷分析日本患者双眼植入三焦点人工晶状体（IOL）后获得的患者报告结局。
53例植入FineVision HP人工晶状体（美国Beaver-Visitec International公司）的患者纳入本前瞻性研究。在术后3个月时，测量屈光（等效球镜度[SE]和柱镜度）、logMAR未矫正远视力（UDVA）和矫正远视力（CDVA）。具体而言，使用NEI VFQ-25、Catquest-9SF和PRSIQ问卷评估患者报告结局。
平均SE和屈光柱镜度分别为0.00±0.22D和-0.07±0.23D。98.11%的眼SE在±0.50D范围内，100%在±1.00D范围内。93.40%的眼散光等于或小于0.50D，100%的眼等于或小于1.00D。单眼UDVA的平均值为-0.05±0.07 logMAR，单眼CDVA的平均值为-0.07±0.06 logMAR。分别有87.74%和92.45%的眼单眼UDVA和CDVA达到20/20或更好，分别有97.17%和98.11%的眼UDVA和CDVA达到20/25或更好。NEI VFQ-25的所有类别结局得分都非常高，平均总体视力、远距离和近距离活动值分别为86.70±6.35、96.23±7.72和92.14±10.74。Catquest-9SF问卷的结局显示，90.57%的患者在日常生活中未报告视力方面的困难，100%的患者目前对自己的视力“非常满意或相当满意”。PRSIQ结局显示，分别有100%、98.11%和98.11%的患者在远、中、近视力方面不需要眼镜或隐形眼镜。
患者报告结局问卷的结果表明，双眼植入FineVision HP人工晶状体的患者视力和与健康相关的生活质量得分较高，眼镜依赖率高，患者满意度高。
